Form 8-K - Current report:
SEC Accession No. 0001628280-24-012736
Filing Date
2024-03-22
Accepted
2024-03-22 16:16:11
Documents
16
Period of Report
2024-03-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20240321.htm   iXBRL 8-K 33670
2 EX-10.1 exh101-baileyx1stamendment.htm EX-10.1 34169
3 EX-10.2 exh102-umsteadx1stamendmen.htm EX-10.2 33397
4 EX-10.3 exh103-avaglianox1stamendm.htm EX-10.3 33725
  Complete submission text file 0001628280-24-012736.txt   286482

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20240321.xsd EX-101.SCH 1922
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20240321_lab.xml EX-101.LAB 22548
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20240321_pre.xml EX-101.PRE 13060
19 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20240321_htm.xml XML 2833
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

EIN.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 24775448
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)